First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors

Transmembrane glycoprotein CD44 is overexpressed in various malignancies. Interactions between CD44 and hyaluronic acid are associated with poor prognosis, making CD44 an attractive therapeutic target. We report results from a first-in-human phase I trial of RG7356, a recombinant anti-CD44 immunoglo...

Descripción completa

Detalles Bibliográficos
Autores principales: Menke-van der Houven van Oordt, C. Willemien, Gomez-Roca, Carlos, van Herpen, Carla, Coveler, Andrew L., Mahalingam, Devalingam, Verheul, Henk M. W., van der Graaf, Winette T. A., Christen, Randolph, Rüttinger, Dominik, Weigand, Stefan, Cannarile, Michael A., Heil, Florian, Brewster, Michael, Walz, Antje-Christine, Nayak, Tapan K., Guarin, Ernesto, Meresse, Valerie, Le Tourneau, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346770/
https://www.ncbi.nlm.nih.gov/pubmed/27507056
http://dx.doi.org/10.18632/oncotarget.11098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346770/
https://www.ncbi.nlm.nih.gov/pubmed/27507056
http://dx.doi.org/10.18632/oncotarget.11098

Ejemplares similares